Columns | Clinical Trial Insights

Half of all drugs in clinical testing are interrupted by in-licensing, co-development, joint venture and M&A arrangements – and they are taking significantly more time to develop.

A discussion of summary findings from the CISCRP 2013 Perceptions & Insights Study

Adaptive trial designs have the potential to transform success rates, but require new operating strategies and practices.

Compliance with reporting clinical trial results is low, and an even larger opportunity is being missed.

Research shows four factors best predict successful patient enrollment in clinical trials.

A new study shows that the cost of implementing protocol amendments should be weighed carefully.

Direction from regulatory agencies would help eradicate wasteful 100 percent source data verification.

Doing more harm than good will ultimately force human subject protection system reform.

Why investigative sites are at financial risk and how it may effect sponsors and CROs.

FDA and EMA may issue new guidelines on sponsor-CRO governance and responsibilities.

A recent survey indicates pharmacists should provide more clinical trial information to patients.

Patients share factors that most inform, educate, and motivate clinical trial participants.

Spending on research exceeds $35 billion, and clinical grant spending now tops $11 billion.

Economic factors and sponsor practices will dramatically alter the investigative site landscape.

The public would be best served if both recognize their own questionable practices.

Out of necessity, providers may finally become valued strategic partners.

Drug development, largely immune to past economic downturns, now faces a different climate.

A look at the vague but time consuming requirements imposed on sites and efforts to ease the burden.

The public considers clinical research important, but they're not fans of the people behind it.

Today's problem-plagued feasibility assessment process is in need of repair.

More complex and demanding protocols are hurting clinical trial performance and success.

Today's sponsors are waking up to the fact that changes made between phases can positively impact R&D.

Lack of minority clinical investigators behind dearth of minority subjects in trials.

Creating sustainable change is the key to fixing this broken process and advancing clinical research.

Individual countries hold the key to finding hot spots in growth regions like Central and Eastern Europe.

Today's CRAs must redefine their roles in the face of changing industry expectations and new technologies.

A new study from Tufts highlights employee and fiscal growth in the industry from 2002 to 2005.

After parting ways in the late 90s, academic medical centers are revisiting industry-sponsored clinical trials.

With today's clinical investigators awash in regulatory burdens, it's high time sponsors provided a lifeboat.

Generalizing fastest drug development strategies and practices.